Treatment recommendations from the NCCN for patients with ALK-positive NSCLC mirror those for EGFR-mutant NSCLC: If the tumor is ALK-positive and the patient has not started systemic treatment, begin treatment with an oral targeted therapy (NCCN, 2016). Here, EGFR is linked to non-small cell lung carcinoma.